SCHEMBL5136929

SCHEMBL5136929

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(Cc1ccccc1)Cc1ccc(O)c(C(=O)OC)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R2 Q9NPC1 1/20 0.37
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 2/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 2/20 0.34
LMNA P02545 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
CNR1 P21554 2/20 0.34
CNR2 P34972 2/20 0.34
STAT3 P40763 2/20 0.34
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TSHR P16473 1/20 0.33
MAPK8 P45983 1/20 0.33
PDK1 Q15118 1/20 0.33
C5AR1 P21730 1/20 0.33
PDE4A P27815 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135244 0.94 KDM4E (0.35) LTB4R2KDM4EALDH1A1NPSR1MEN1
SCHEMBL5134753 0.92 STAT3 (0.40) LTB4R2STAT3TSHRPDK1C5AR1
SCHEMBL5136872 0.91 LMNA (0.40) LTB4R2ALDH1A1NPSR1MEN1POLB
SCHEMBL5136034 0.89 CXCR3 (0.36)
SCHEMBL5136262 0.88 TLR7 (0.41)
SCHEMBL5137573 0.86 CXCR3 (0.39) ALDH1A1MEN1POLBKMT2ALMNA
SCHEMBL5134566 0.83 TSHR (0.41) LTB4R2KDM4EALDH1A1MEN1KMT2A
SCHEMBL5135282 0.83 ALDH1A1 (0.37) LTB4R2KDM4EALDH1A1NPSR1MEN1
SCHEMBL650145 0.83 LPAR1 (0.40) KDM4EALDH1A1MEN1KMT2AMAPT
SCHEMBL5135309 0.83 TLR7 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed